Free Trial

Coherus BioSciences (CHRS) Stock Forecast & Price Target

$2.11
+0.03 (+1.44%)
(As of 05/22/2024 ET)

Coherus BioSciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 6 Analyst Ratings

Consensus Price Target

$8.83
318.64% Upside
High Forecast$12.00
Average Forecast$8.83
Low Forecast$6.00
TypeCurrent Forecast
5/24/23 to 5/23/24
1 Month Ago
4/24/23 to 4/23/24
3 Months Ago
2/23/23 to 2/23/24
1 Year Ago
5/24/22 to 5/24/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$8.83$9.29$11.22$16.14
Forecasted Upside318.64% Upside185.79% Upside196.26% Upside137.85% Upside
Get Coherus BioSciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.

CHRS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CHRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Coherus BioSciences Stock vs. The Competition

TypeCoherus BioSciencesMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.69
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside318.64% Upside704.29% Upside8.71% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/13/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$8.00 ➝ $7.00+258.97%
5/10/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$11.00 ➝ $12.00+555.73%
1/23/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$11.00 ➝ $9.00+275.00%
11/8/2023Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
10/23/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$8.00 ➝ $7.00+112.12%
10/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$7.00 ➝ $6.00+59.57%
7/24/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$12.00+179.72%
3/28/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$11.00+83.33%
3/14/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$21.00 ➝ $23.00+261.07%
11/14/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$13.00 ➝ $11.00+41.21%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:40 AM ET.

CHRS Frequently Asked Questions

What is Coherus BioSciences's stock forecast and purchase recommendation?

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Coherus BioSciences is $8.83, with a high forecast of $12.00 and a low forecast of $6.00. The consensus rating for Coherus BioSciences stock is Moderate Buy based on the current 1 hold rating and 5 buy ratings for CHRS. Learn more on CHRS's analyst rating history.

Do Wall Street analysts like Coherus BioSciences more than its competitors?

Analysts like Coherus BioSciences more than other "medical" companies. The consensus rating score for Coherus BioSciences is 2.83 while the average consensus rating score for "medical" companies is 2.69. Learn more on how CHRS compares to other companies.

Does Coherus BioSciences's stock price have much upside?

According to analysts, Coherus BioSciences's stock has a predicted upside of 210.44% based on their 12-month stock forecasts.

What analysts cover Coherus BioSciences?

Coherus BioSciences has been rated by research analysts at HC Wainwright, and Truist Financial in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:CHRS) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners